Introduction mda-7/IL-24 displays all the characteristics of a typical cytokine including secretion, receptor binding, activation of JAK/STAT signaling and modulation of growth characteristics of responsive cells (Huang et al., 2001; Caudell et al., 2002; Sauane et al., 2003b) . This molecule was initially discovered using a differential gene expression subtraction screening strategy to identify and clone genes upregulated during melanoma cell differentiation (Jiang and Fisher, 1993; Jiang et al., 1995) . Owing to no obvious homology to sequences in public databases, it was initially not apparent that mda-7 was a cytokinerelated molecule. Currently, in addition to biochemical data demonstrating secretion and cytokine properties, location of mda-7/IL-24 in an IL-10 family-related genomic cluster on human chromosome 1q22/1q23 has emphasized its actual functional identity (Blumberg et al., 2001; Huang et al., 2001) . Thus, the recently recognized IL-10 family comprises six members including IL-10, IL-19, IL-20, IL-22, mda-7/IL-24 and IL-26 (Gallagher et al., 2000; Blumberg et al., 2001; Pestka et al., 2004) , none of which share significant homology at the primary amino-acid level, but which clearly possess functional and structural conservation justifying their subclassification as a distinct cytokine subfamily. Recent work has focused on determining the actual physiological roles of each molecule and the extent of their functional overlap or distinctiveness (Caudell et al., 2002; Fickenscher et al., 2002; Kisseleva et al., 2002; Kotenko, 2002; Parrish-Novak et al., 2002; Sarkar et al., 2002a; Pestka et al., 2003 Pestka et al., , 2004 Sauane et al., 2003b) .
A unique property of mda-7/IL-24 is its ability to induce apoptosis specifically in transformed cells while having no apparent harmful effect on normal counterparts, including normal human tissues in in vivo clinical trial contexts (Jiang et al., 1996a; Su et al., 1998; Madireddi et al., 2000; Saeki et al., 2000; Chada et al., 2001; Huang et al., 2001; Lebedeva et al., 2002; Sarkar et al., 2002b; Fisher et al., 2003; Nemunitais, 2003) . This unique property is under intense scrutiny from the viewpoint of mechanism of tumor cell specificity to more effectively translate mda-7/ IL-24 from the laboratory into the clinic as a cancer gene therapeutic Fisher et al., 2003; Nemunitais, 2003) . Various reagents have been raised to address the functional activity and transformed cellspecificity of mda-7/IL-24 including an adenovirus (Jiang et al., 1996b) used in clinical trails as well as plasmid expression vectors (Jiang et al., 1995 (Jiang et al., , 1996b , antibodies and various forms of purified protein utilized in the laboratory (Caudell et al., 2002; Parrish-Novak et al., 2002; Ramesh et al., 2003; Yacoub et al., 2003a Yacoub et al., , 2004 .
Schistosoma japonicum derived Glutathione-S-transferase (GST)-tagged fusion proteins have several favorable attributes that facilitate protein expression and purification that are not achievable for proteins expressed in untagged native form (Smith and Johnson, 1988; Zhan et al., 2001) . Fusions can be easily expressed in the Escherichia coli system with high yield and this approach has been effective for a wide range of biologically active peptides or proteins, without disrupting their native activity (Zhan et al., 2001) . Recent data indicate that GST has high transduction efficiency in various cell types and can be used successfully for intracellular delivery of biologically active peptides (Namiki et al., 2003) . A GST-MDA-7 fusion protein was expressed and purified from a bacterial expression system to generate antigen for producing antibodies recognizing MDA-7/IL-24 protein. In the course of these experiments, analysis was also performed to determine if this purified protein had biological activity. These studies which are described in the following sections, contrasts with reports of activity of purified MDA-7/IL-24 protein expressed and purified by three independent groups using other expression systems (Caudell et al., 2002; Parrish-Novak et al., 2002; Ramesh et al., 2003) . Our results confirm that signaling events leading to susceptibility to GST-MDA-7-induced apoptosis are p38MAPK-dependent in transformed cellspecific killing. Data reported here indicate that GST-MDA-7 is taken up by cells and can internalize. Moreover, all pancreatic cancer cells tested with GST-MDA-7 protein are directly susceptible to killing, whereas these cells display resistance to killing following infection by Ad.mda-7 . In these contexts, the GST-MDA-7 fusion protein provides a valuable reagent for analysing the molecular basis of cancer-specific apoptosis-inducing properties of this novel molecule, which previously was a property restricted to delivery by adenoviral expression vectors. In addition, the ability of GST-MDA-7 to induce cancer cell killing in specific cancer cells, whereas adenovirus mediated mda-7/IL-24 does not induce this property, offers potential to increase the therapeutic efficacy of this intriguing clinically relevant cytokine.
Results
GST-MDA-7 fusion protein displays cancer cell-killing specificity and is able to distinguish between transformed and normal cells
The immortalized prostate epithelial cell line P69 and the prostate tumor cell line DU-145 were treated under identical conditions to determine the effect and specificity of GST-MDA-7 protein. After determining the appropriate range of protein needed for activity (data not shown), cells were treated with a predetermined optimum protein concentration (50 ng/ml) and observed daily until cytotoxicity was apparent, which occurred between 48 and 72 h post-treatment compared to cells treated with unfused control GST protein (Figure 1a) . Minimal or no cytotoxicity was observed in GST treated normal-or tumor-derived cells. In comparison, significant cell killing was evident in the human prostate cancer cell line, DU-145, after treatment with GST-MDA-7 protein, which had little effect on resistant P69 cells. From these results, it appears that the bacterially derived protein has comparable properties, in terms of cancer cell-specificity, to protein derived from Ad.mda-7.
To confirm that the observed cell killing, following treatment with GST-MDA-7 resulted from induction of apoptosis, FACS analysis was performed on susceptible DU-145 prostate cancer and resistant P69 cells. Cells were treated in parallel with GST and GST-MDA-7 protein at 50 ng/ml after plating at 2 Â 10 6 cells/6-cm dish utilizing one plate for each time point. Samples were withdrawn at various time points and fixed in 80% ethanol after trypsinization. Cells were stained with propidium iodide and FACS analysis was performed to determine the proportion of apoptotic cells in the population as a function of time (Figure 1b and c) . Treatment of P69 cells up to 96 h with GST-MDA-7 gave a similar FACS profile as untreated or GST control treated cells (Figure 1b) , while DU-145 treated cells showed a 50% A o population at 96 h compared to less than 21% for untreated and GST-treated populations ( Figure 1c) . The extent of cell killing is likely underestimated since a certain proportion of cells were highly fragmented or lysed following GST-MDA-7 treatment and could not be analysed by FACS. A certain proportion of dead cells were observed in the untreated and GST-treated samples at later time points due to confluence and cell overgrowth. These data indicated that susceptible cells treated with GST-MDA-7 undergo apoptotic death.
Annexin V staining was performed on susceptible prostate cancer cell lines and resistant normal immortal P69 cells. Annexin V staining confirmed increases in early apoptotic cells (24 h) as a function of GST-MDA-7 treatment in PC-3, DU-145 and LNCaP cells (Figure 1d ). In contrast, no significant change in early apoptotic cells was apparent in P69 cells using the same experimental protocol.
GST-MDA-7 induces apoptosis in mutant cell lines defective in the JAK/STAT pathway We investigated the specific requirements of the JAK/ STAT pathway in GST-MDA-7-mediated killing by employing cell lines functionally deficient for JAK/ STAT. These included a human fibrosarcoma cell line 2f TGH (parental) and corresponding mutant cell lines derived from it, including U1A (lacking Tyk2), U3A (IFN-unresponsive, lacking STAT1), and U4A (lacking JAK1). The human prostate cancer cell PC-3, that does not express STAT3 (Spiotto and Chung, 2000) was used to complete the known spectrum of mda-7/IL-24-mediated pathway components. These cell lines were treated with GST-MDA-7 and viability was analysed by using an MTT cell proliferation assay. In addition, two inhibitors of tyrosine kinases, Genistein and tyrphostin AG18 as well as the JAK-selective inhibitor, AG490, were utilized (Sauane et al., 2003a) . All of these cell lines were susceptible to GST-MDA-7 (Figure 2a , compare GST to GST-MDA-7). These data provide an independent means of confirmation that the activation of JAK/ STAT induced by mda-7/IL-24 can be separated from cell apoptosis induced after GST-MDA-7 treatment, since the cells tested have inactivating mutations in JAK/STAT signaling components. DU-145 cells were also treated with GST-MDA-7 protein during different periods of time and analysed for activation of the JAK/ STAT pathway by determining the extent of STAT3 phosphorylation. As evident in Figure 2b , treatment with purified GST-MDA-7 protein does not induce phosphorylation of STAT3, whereas treatment with fibroblast interferon (1000 U/ml) induces a temporal induction of STAT3 phosphorylation.
Cytotoxicity of bacterial GST-MDA-7 protein is inhibited by treatment of cells with the p38MAPK inhibitor SB203580
As previously reported, inhibition of the p38MAPK pathway by pharmacological inhibitors or dominantnegative adenovirus blocked the ability of Ad.mda-7 to kill different cancer cell types, including PC-3 (Sarkar et al., 2002b) . PC-3 human prostate cancer-derived cells were incubated in the absence or presence of SB203580 (2 mM), 24 h before treatment with GST or GST-MDA-7 protein and the extent of cytotoxicity was determined (Figure 3a and b). Under these experimental conditions, a significant inhibition of GST-MDA-7-induced killing of PC-3 prostate cancer cells was obtained following Mechanistic aspects of mda-7/IL-24 M Sauane et al SB203580 treatment. These results indicate that GST-MDA-7 protein most probably acts in a comparable manner as Ad.mda-7 by activating the p38MAPK pathway as one of the potential pathways by which transformed cell-specific apoptosis is induced.
GST-MDA-7 protein is able to kill human pancreatic cancer cells in the absence of ablation of Ras signaling by antisense K-Ras
We previously reported that human pancreatic cancerderived cell lines are not susceptible to direct killing by Ad.mda-7 (100 PFU/cell) . We further showed that lack of killing was due to absence or very low amount of MDA-7/IL-24 protein expression. Treatment of resistant cells with a combination of antisense K-ras (phosphothiorate oligonucleotides or a plasmid expressing this AS molecule) and Ad.mda-7 vector caused killing which correlated with reappearance of MDA-7 protein. We presently demonstrate that treatment of these resistant cells with purified GST-MDA-7 protein is able to induce cell death directly, strengthening the hypothesis that a translational block might be operational in these and additional MDA-7/ Figure 4a ). Since all of the pancreatic cancer cells treated with GST-MDA-7 protein, irrespective of their K-ras status, are directly susceptible to killing, it appears that cells or tumors that appear to be resistant to infection with Ad.mda-7, might still be killed following direct exposure to purified protein. This observation suggests added clinical significance in a resistant or uninfectable (by adenovirus) tumor context. The human pancreatic cancer cell line BxPC-3 is completely resistant to killing by Ad.mda-7 either in the presence or absence of K-ras ablation . This cell line is wild type for K-ras and does not express detectable levels of MDA-7 protein after combination treatment with antisense K-ras þ Ad.mda-7. However, exposure of these cells to GST-MDA-7 protein results in cell killing, as shown in Figure 4 . Treatment of BxPC-3 and other normal and cancer cell types (not shown) with bacterially expressed and purified GST-MOB-5, the rat orthologue of mda-7 (Wang et al., 2002) , showed no cytotoxic effects on cells and was comparable to treatment with unfused GST protein (Figure 4b ). This protein derived from the rat sequence was also a bacterially expressed and purified GST fusion, which had no effect on cell viability under conditions where GST-MDA-7 caused a significant amount of cancerspecific cell death. Therefore, cancer-cell specificity of mda-7/IL-24 is further strengthened following parallel utilization of a closely related molecule mob-5 (B80% similar) derived from rat.
Apoptosis induction by exogenously administered GST-MDA-7 protein is likely due to rapid uptake by cells DU-145 cells were treated with control GST or GST-MDA-7 fusion proteins following plating on coverslips. Cells were washed thoroughly with PBS to remove externally bound material before fixation. Parallel sets of samples were reacted with anti-GST and anti-MDA-7 antibody followed by Alexa Fluor 488 tagged secondary antibody for immunofluorescent detection of protein ( Figure 5 ). Several time points were utilized to determine kinetics of protein uptake and additional controls including secondary antibody alone, and nonsusceptible FM-516-SV normal immortal human melanocytes were used in parallel (not shown). When analysed with anti- 1000 U/ml), GST (50 ng/ml) or GST-MDA-7 (50 ng/ml) treatment from 15 min to 2 h. Samples (50 mg) were run on 10% SDS-PAGE, transferred to a nitrocellulose membrane and probed with rabbit anti-phospho-STAT3 and anti-STAT3 antibodies as described in Materials and methods Mechanistic aspects of mda-7/IL-24 M Sauane et al GST antibody, both control GST protein as well as GST-MDA-7 were visualized inside cells in extranuclear locations. Samples processed in parallel, but reacted with anti-MDA-7 specific antibody, indicated an intracellular localization of GST-MDA-7 protein. Specificity is demonstrated due to lack of detection of protein in GST-treated samples reacted with anti-MDA-7 antibody. It therefore appears that both GST as well as BxPC3 (wild-type K-ras) human pancreatic cancer cell line was plated in triplicate at 1 Â 10 6 cells/6 cm dish. Surviving cells were counted 72 h after treatment with purified GST, GST-MDA-7, and GST-MOB-5 protein expressed and purified under identical conditions. Untreated cells (UT) were used as an additional control. Cell counts were performed using trypan blue dye exclusion to enumerate the number of surviving cells after treatment Mechanistic aspects of mda-7/IL-24 M Sauane et al GST-MDA-7 fusion protein are internalized by cells. It is unclear if this is a receptor-mediated process though a more likely possibility is that the GST moiety facilitates uptake of protein by cells, as recently reported (Namiki et al., 2003) .
MDA-7/IL-24 localizes to the ER/Golgi compartments
Based on previous results indicating that apoptosis induced by mda-7/IL-24 have a potent intracellular mode of action and this molecule is active in inducing transformed cell-specific apoptosis even without secretion Sieger et al., 2004) , it was important to determine the subcellular location of GST-MDA-7 protein. Therefore, comparative subcellular localization of MDA-7/IL-24 was analysed in DU-145 cells after treatment with protein for 24 h. GST-MDA-7 protein was detected only in extra-nuclear regions of individual cells. While there was a light background cytoplasmic staining, protein location primarily overlapped that of the endoplasmic reticulum (ER) stained with anti-calreticulin. The colocalization of MDA-7/IL-24 in the Golgi apparatus was also detected via colocalization with anti-GM130 staining. However, no colocalization of MDA-7/IL-24 in mitochondria labeled with MitoTracker red occurred, confirming staining specificity in DU-145 cells (Figure 6 ). Similar localization results were obtained using the GST-MDA-7 protein in P69 cells, suggesting that differential localization of MDA-7 following treatment with this fusion protein may not be a contributing factor in determining the differential sensitivity of cancer versus normal cells to GST-MDA-7 (unpublished data).
GST-MDA-7 protein is able to kill human breast cancer cells and it has radiosensitizing effects similar to Ad.mda-7
Ionizing radiation has been shown to enhance the killing effect of purified GST-MDA-7 protein in glioma cells in vitro (Su et al., 2003; Yacoub et al., 2003b Yacoub et al., , 2004 . To test whether GST-MDA-7 is able to induce a similar effect in breast cancer cells lines and whether radiation can modulate apoptosis, first MDA-MB-231 cells were treated with bacterially synthesized GST-MDA-7 at different concentrations to determine effect on cell growth. As shown in Figure 7a , GST-MDA-7, but not GST, induced a dose-dependent decrease in viability in MDA-MB-231 cells as reflected by MTT assay. MDA-MB-231 cells were treated with bacterially synthesized GST-MDA-7 followed by exposure to ionizing radiation (Figure 7b ). GST-MDA-7 suppressed MDA-MB-231 cell growth that was enhanced in a greater that an additive fashion by ionizing radiation (Figure 7b ). The direct growth inhibitory effect of purified protein in additional breast cancer cells was observed when MCF-7, T47D and MDA-MB-157 breast tumor cells were treated with the GST-MDA-7 protein (Figure 7c ). In contrast, no significant change in viability or growth was observed following treatment of the normal HBL-100 breast epithelial cell line with GST-MDA-7 (Figure 7c ). These data provide further support for equivalent cancer-specific cell killing when mda-7/IL-24 is applied to cells as a GST-MDA-7 fusion protein produced in bacteria. Moreover, cancer-cell specific killing in breast cancer cells by GST-MDA-7, as previously shown using Ad.mda-7 (Su et al., 1998), occurs in a p53-independent Figure 5 Internalization of GST and the MDA-7 protein, respectively, after treatment with GST or GST-MDA-7: GST and MDA-7 protein localization was analysed by indirect immunofluorescence after treatment of DU-145 cells with purified GST (24 h posttreatment) or GST-MDA-7 protein (2 and 24 h post-treatment). Cells were washed, fixed, and GST or GST-MDA-7 protein, respectively, was detected by indirect immunofluorescence using anti-GST (three panels on top) or anti-mda-7/IL-24 antibody (three panels on bottom)
Mechanistic aspects of mda-7/IL-24 M Sauane et al manner, that is, MCF-7 (is wild-type p53), MDA-MB-157 (is null for p53), and MDA-MB-231 and T47D (are mutant for p53).
Discussion
Considerable interest exists in elucidating the mechanism by which mda-7/IL-24-mediated apoptosis differentiates between normal and transformed cells. Precisely, how mda-7/IL-24 induces this selective effect is clearly very complex and can vary in a cell-type and cancer-specific context (Sarkar et al., 2002a; Fisher et al., 2003; Sauane et al., 2003b) . The antitumor cell activity of the molecule can function independently of JAK/ STAT signal transduction pathways that are classically involved in cytokine-mediated activities, now documented using GST-MDA-7 protein as well as previously reported using adenoviral delivery of mda-7/IL-24 (Sauane et al., 2003a) . Additionally, we previously demonstrated by sensitive RT-PCR methodology that apoptosis could be induced in tumor cells not expressing detectable levels of IL-20/IL-22 receptors that bind to MDA-7/IL-24 (Sauane et al., 2003a) . Moreover, an adenovirus vector expressing a nonsecreted version of MDA-7/IL-24 protein was generated via deletion of its signal peptide, and this nonsecreted protein was as effective as wild-type secreted MDA-7/IL-24 in inducing apoptosis , confirming that mda-7/ IL-24-mediated apoptosis can be triggered through intracellular localization as well as via secretion. Our results and recent studies by others clearly reveal that intracellular MDA-7/IL-24 is active in inducing transformed cell-specific apoptosis, probably through mechanisms overlapping and possibly involving pathways associated with ER-stress or the unfolded protein response mechanism Sieger et al., 2004) . Induction of GADD genes is classically associated with the stress response including ER-stress pathways. Induction of GADD genes and further upstream events such as activation of p38MAPK was shown to be induced in a transformed cell-specific Figure 6 Localization of the MDA-7 protein after treatment with GST-MDA-7: MDA-7/IL-24 protein localization was analysed by indirect immunofluorescence after treatment of DU-145 cells with GST-MDA-7. At 48 h postinfection, cells were fixed and MDA-7/IL-24 protein was detected by indirect immunofluorescence using anti-mda-7/IL-24 antibody. Images of Golgi, ER and mitochondria were obtained using anti-G130, anti-calreticulin, and MitoTracker, respectively, as described in Materials and methods. Images of the different compartments and mda-7/IL-24 were merged to determine extent of colocalization
Mechanistic aspects of mda-7/IL-24 M Sauane et al manner after Ad.mda-7 infection (Sarkar et al., 2002b) . Furthermore, Ad.mda-7 infection upregulated the inositol 1,4,5-trisphosphate receptor (IP3R) in H1299 cells . IP3R is an intracellular calcium-release channel implicated in apoptosis and localized in the ER. Finally, nonsecreted protein and wild-type secreted MDA-7/IL-24 localizes in the Golgi/ER compartments , as does the bacterially expressed and purified GST-MDA-7 fusion protein.
Previous studies have documented that secreted MDA-7/IL-24 from supernatants of HEK 293 cells has biological activity. Specifically, in human PBMCs, MDA-7/IL-24 functions as a pro-Th1 cytokine and induces production of IFN-g, IL-6, and tumor necrosis factor a (Caudell et al., 2002) . MDA-7/IL-24 is also a potent antiangiogenic effector in vitro as well as in vivo . The studies listed above have likely utilized purified secreted native protein at relatively lower concentrations than achieved via Ad.mda-7 infection possibly due to limitations of the source of production (a stably transfected 293 cell line, Caudell et al., 2002) . Purified MDA-7/IL-24 used in these studies was able to activate phosphorylation of STAT1/3. However, none of these studies, utilizing native secreted MDA-7/IL-24 demonstrated growth inhibition or apoptosis induction (Caudell et al., 2002; Ramesh et al., 2003) . Parrish-Novak et al. (2002) demonstrated that in NIH:OVCAR-3, MDA-7/ IL-24 inhibited cell growth only at doses above 600 pM. This cytostatic effect employs an alternative pathway since STAT1/3 activation was not observed and the authors speculate that it probably occurs through nonclassical receptor activation or might be receptor independent. Further, this growth inhibitory activity was reversible. To try to dissect the pathways involved in the growth inhibitory activity of MDA-7/IL-24 using adenoviral delivery or via purified bacterial GST-fusion protein, it is clear that we need to distinguish between physiological and supraphysiological expression of MDA-7/IL-24 . In the work by Caudell et al (2002) , treatment of primary human PMBCs with bacterial or yeast-derived protein required a relatively high amount of protein (mg/ml range) to elicit responses such as secretion of secondary cytokines (IL-6, TNF-a and IFN-g) compared to subsequent studies described in the same report performed utilizing native MDA-7/IL-24 protein derived from tissue culture supernatants of a stably transfected cell line (Caudell et al., 2002) . As mentioned above, purified MDA-7 derived-protein from tissue culture supernatant and others, including alternate bacterial (6-Histidine tagged) and baculovirally derived sources have demonstrated cytokine-related activity including receptor binding (Wang et al., 2002) and JAK/STAT activation but not transformed cellspecific killing that we have obtained with the GSTfusion described in this report. The reasons for the difference in activity are presently unclear, but might involve factors such as protein stabilization and internalization described below.
Experiments reported here have validated the equivalence of bacterially expressed GST-MDA-7 fusion and adenovirally expressed untagged MDA-7/IL-24 protein in terms of their selective antitumor properties. A significant number of peptides or proteins have been successfully expressed as GST fusion proteins without losing their biological activity (Smith and Johnson, Figure 7 Enhanced radiation-induced cell killing in breast cancer cells treated with GST-MDA-7. (a) MDA-MB-231 cells were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments indicated versus untreated cells. (b) MDA-MB-231 cells were treated with GST-MDA-7 or GST and 24 h after cells were irradiated (3, 6, 9 Gy). Cells were collected 96 h after irradiation and viability was determined by MTT assay. (c) HBL-100, MDA-MB-157, MDA-MB-231, T47D, and MCF-7 were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments indicated versus untreated cells. An average of three independent experiments is shown 7s.d
Mechanistic aspects of mda-7/IL-24 M Sauane et al 1988). Studies using GST-driven crystallization have also shown that the final crystal structure of the fused segment remains in their native form (Zhan et al., 2001) . Like Ad.mda-7 expressed MDA-7/IL-24 protein, our GST fusion protein can induce killing in cancer-derived cell lines while exerting minimal effects in nontransformed cells (Figure 1 ) and death occurs via apoptosis as determined by Annexin V staining and FACS analysis, which distinguishes apoptotic from necrotic cell death (Su et al., 2003) .
In the context of tumor cell killing, GST-MDA-7 also operates in a similar way as does MDA-7/IL-24 via JAK/STAT-independent and MAPK-dependent pathways (Figures 3 and 4) as has previously been demonstrated for the mda-7/IL-24 gene product delivered by an adenovirus (Sarkar et al., 2002b; Sauane et al., 2003a) . Furthermore, treatment with GST-MOB-5 (rat orthologue of mda-7 having B80% homology (Wang et al., 2002) , purified under the same conditions, did not induce cytotoxic effects in cells and was comparable to treatment with GST protein, indicating that the observed apoptotic effects are not attributed to the novel modifications of the fusion protein but rather are likely a consequence of the activity of the MDA-7/IL-24 moiety of the fusion. The GST-tag might, however, contribute to both stability as mentioned above as well as facilitation of protein uptake. There is also a possibility that the uptake process is receptor mediated but the likelihood of currently recognized cognate mda-7/IL-24 receptor participation in this process is not very strong. In general, the data shown here indicate that GST-MDA-7 is functionally equivalent to native MDA-7/IL-24 protein with respect to its tumor-killing attributes.
Pancreatic cancer is one of the most lethal forms of all malignancies, with the lowest probability of survival (Blaszkowsky, 1998; Regine et al., 1998; Hilgers and Kern, 1999; Lorenz et al., 2000; Rosenberg, 2000) . Treatment with Ad.mda-7 alone has no effect on these tumor cells despite the pervasive antitumor toxicity of MDA-7/IL-24 protein, and it was postulated that this resistance is due to interference of mda-7/IL-24 translation or protein stability by the mutant K-ras pathway present in 85-95% of tumors . While MDA-7/IL-24 protein was not detected after infection with Ad.mda-7, combined infection with antisense K-ras (phosphorothioate oligonucleotides or an antisense K-ras expression construct) in pancreatic cancer cells resulted in production of MDA-7/IL-24 protein and consequently cell death . We demonstrated that direct application of MDA-7/IL-24 proteins in the form of GST-MDA-7 could kill mutant K-ras pancreatic cancer cells (Figure 4) . Hence, these studies establish that when a sufficient amount of active MDA-7/IL-24 protein is delivered to pancreatic tumor cells, killing is effective and the source of their apparent resistance can be most likely attributed to interference with MDA-7/IL-24 protein translation and/or stability by the K-ras-activated pathway.
Cancer gene therapy using Ad.mda-7 has significant promise and based on initial successes continues to be evaluated in Phase I/II clinical trials Nemunitais, 2003) . The potential use of GST-MDA-7 protein as a therapeutic is intriguing, since it can enlarge the existing MDA-7/IL-24 therapeutic scope to cover tumors resistant to or uninfectable by Ad.mda-7. It is presently demonstrated that direct application of GST-MDA-7 can kill pancreatic cancer cell lines previously resistant to Ad.mda-7 (Figure 4) . Another example is renal cell carcinoma (RCC), where recent studies demonstrated that Ad.mda-7 did not affect RCC proliferation due to weak infectivity, but GST-MDA-7 caused a dose-dependent growth suppression (Yacoub et al., 2003b (Yacoub et al., , 2004 . Additional work has demonstrated that both Ad.mda-7 as well as the GST-MDA-7 fusion protein is able to radiosensitize primary human glioblastoma cells to comparable extents (Su et al., 2003; Yacoub et al., 2003a Yacoub et al., , 2004 . When analysed with anti-GST antibody, both control GST protein as well as GST-MDA-7 is visualized inside cells in extranuclear locations. Samples processed in parallel but reacted with anti-MDA-7 antibody show an intracellular localization of GST-MDA-7 protein. Specificity is demonstrated due to lack of detection of protein in GST-treated samples reacted with anti-MDA-7 antibody. It therefore appears that GST as well as GST-MDA-7 fusion proteins are internalized by cells. It is unclear if this is a receptor-mediated process, although a more likely possibility is that the GST moiety facilitates uptake of protein by cells as recently reported (Namiki et al., 2003) .
The retention of biological activity and particularly, cancer cell specificity of bacterially produced GST-MDA-7 was unexpected given the large size of the amino-terminally located tag and its likely interference in receptor binding. However, our recent findings that the mda-7/IL-24 gene functions efficiently in the absence of secretion following mutation of its signal peptide and the ability of GST-fusion proteins to enter cells could explain why GST-MDA-7 demonstrates cancer-cell-specific apoptosis inducing activity. In these contexts, the availability of this bioactive fusion protein allows for more detailed kinetic studies of MDA-7/IL-24 action, such as varying exposure time, which is difficult to achieve with Ad.mda-7. The purified active protein can provide an additional reagent of some utility in the ongoing analysis and characterization of mda-7/IL-24 as a potential cancer gene therapeutic. Accordingly, the observation that purified GST-MDA-7 protein is able to kill Ad.mda-7-resistant pancreatic cancer cells is particularly relevant. This indicates potential complementarity in utilization of two distinct reagents (Ad.mda-7 and GST-MDA-7) for analytical and therapeutic uses. Additionally, now having this unique combination of reagents in hand to deliver mda-7/IL-24 provides an unparalleled opportunity for defining the biochemical and molecular events controlling cancer-cell specificity of this clinically pertinent cytokine.
Materials and methods

Cell lines and culture conditions
PC-3, LNCaP and DU-145 (human prostate cancer), 2f TGH (human fibrosarcoma) and corresponding mutant sublines U1A, U3A, U4A and U5A (Darnell et al., 1994) (kind gift of G Stark, Cleveland Clinic, OH, USA) were grown in Dulbecco's modified Eagle's medium/F12 (DMEM/F12) supplemented with 10% FBS at 371C in a humidified 5% CO 2 incubator. Human pancreatic carcinoma cell lines (AsPC-1, BxPC-3, MIA PaCa-2, and PANC-1) were maintained in RPMI 1640 medium containing 10% FBS, antibiotics and Lglutamine (Blumberg et al., 2001) . Normal human breast epithelial cells and human breast cancer-derived lines MCF-7, T47D, MDA-MB-231, and MDA-MB-157 were grown in DMEM containing 10% FBS.
Synthesis of GST-MDA-7
Standard cloning procedures were used to generate a bacterial expression vector comprising in-frame fusion of the mda-7/IL-24 open reading frame 3 0 to the GST open reading frame in GST-4T2 vector (Amersham Pharmacia, NJ, USA), using BamH1 and Not1 sites introduced into the mda-7/IL-24 ORF by PCR. Expression of protein was performed by inoculating an overnight culture at 1 : 100 dilution followed by incubation at 251C until an A 600 of 0.4-0.6 nm was reached, followed by induction with 0.1 mM isopropyl-1-thio-b-D-galactopyranoside (IPTG) for 2 h. Cells were harvested by centrifugation and sonicated in PBS followed by centrifugation to obtain soluble protein. The lysates were bound to a glutathione-agarose column (Amersham Pharmacia, NJ, USA) at 41C for 2 h followed by washing with 50 volumes of PBS and 10 volumes of PBS with 500 mM NaCl. Passing 20 mM-reduced glutathione through the column and collecting 1 ml fractions performed elution of bound protein. Fractions were analysed by gel electrophoresis, and positive samples were dialysed against 1000 volumes of PBS for 4 h with one change, followed by 500 volumes of DMEM for 4 h. Protein concentration was estimated by Bradford assays, as well as gel electrophoresis, in conjunction with Coomassie blue staining. Samples were tested for activity using GST protein as control. An antipeptide, rabbit polyclonal antibody was raised to specifically detect MDA-7 protein and was used in these studies at 1 : 1000 dilution for immunoblotting and 1 : 200 dilution for immunofluorescence.
MTT assays
Cells were plated in 96-well dishes (1 Â 10 3 cells/well) in DMEM/F12 containing 10% FBS and allowed to attach for 12 h prior to GST or GST-MDA-7 treatment, usually at 25-50 ng/ml. Treatment with inhibitors was initiated 1 h before treatment with protein. During a 5-7-day-treatment period, the medium was changed twice with fresh inhibitor containing medium at days 3 and 6. Cell growth and viable cell numbers were monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining as described (Lebedeva et al., 2000 (Lebedeva et al., , 2002 . The resulting absorbance measured at 595 nm is directly proportional to the number of viable cells.
Annexin-V binding assay
Cells were trypsinized and washed once with complete media. Aliquots of the cells (5 Â 10 5 ) were resuspended in complete medium (0.5 ml) and stained with FITC-labeled Annexin-V (kit from Oncogene Research Product, Boston, MA, USA) according to the manufacturer's instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. The FACS assay was performed immediately after staining.
FACS analysis
Cells were trypsinized and washed once with complete media. Aliquots of cells (5 Â 10 5 ) were resuspended in complete medium (0.5 ml). Propidium iodide (PI) was added to the samples. FACS assays were performed immediately after staining. The percentage of cells in the apoptotic (A o ) fraction was calculated using CellQuest software (Becton Dickinson).
Western blot analyses
Cell lines were grown on 10-cm plates and protein extracts were prepared with RIPA buffer containing a cocktail of protease inhibitors. A total of 50 mg of protein was applied to 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with polyclonal antibodies to MDA-7/IL-24, phospho-STAT3 and total STAT3 (Cell Signalling Technology, MA, USA).
Immunofluorescence analyses
DU-145 cells were grown in chamber slides (Falcon-BD, CA, USA) fixed with 2% paraformaldehyde, permeabilized by 0.1%. Triton X-100, and then incubated with primary antibodies: anti-rabbit mda-7, GM130 (BD Pharmingen, CA, USA), LAMP1/2 (Santa Cruz, CA, USA), Calreticulin (BD Pharmingen, CA, USA) and Mitrotrack marker (Molecular Probes, Eugene, OR, USA). FITC-conjugated donkey antimouse IgG and anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) were used for visualization on a Zeiss LSM 510 fluorescence microscope.
